Obesity Treating Neuromodulation System Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Deep Brain Stimulator, Spinal Cord Stimulator, Vagus Nerve Stimulator, Splanchnic Nerve Stimulator, Autonomous Nerve Stimulator, Other); End user (Hospitals, Clinics, Ambulatory Surgical Centers); End user (Hospitals, Clinics, Ambulatory Surgical Centers), and Geography
Report Code: TIPRE00021865
| No. of Pages: 150
| Category: Medical Device
| Status: Upcoming
Obesity is a condition characterized by an excess of body fat that is generally described as 20% or more of one's ideal weight. Obesity is a health risk that prevents people from performing daily tasks. Excess weight is linked to a variety of diseases such as hypertension, stroke, diabetes, heart attack, osteoarthritis, and others. Obesity is defined by the WHO as having a body mass index of 30. Obesity is the fifth leading cause of death, according to the World Health Organization. It has become a major public health concern around the world as a result of a variety of factors like genetics and human behaviors. Neuromodulation has shown some potential for the treatment of obesity, and it is less invasive than surgical options such as gastric banding and gastric bypass. The appetite signal between the gut and the brain is manipulated by the obesity-treating neuromodulation system.
Factors driving the growth of the obesity treating neuromodulation system market are the growing prevalence of obese population., coupled with rising awareness among people regarding benefit of neuromodulation system over tradition treatment. However, the hesitation among people to get implant for obesity treatment and complications associated with the neuromodulation devices is expected to hamper the growth of the market. Moreover, increasing adoption of novel technology and advancement in the neuromodulation devices and rising product approval is anticipated to boost the market growth.
The "Obesity Treating Neuromodulation System Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of obesity treating neuromodulation system market with detailed market segmentation by product type and end user. The obesity treating neuromodulation system market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in obesity treating neuromodulation system market and offers key trends and opportunities in the market.
The obesity treating neuromodulation system market is segmented on the basis of product type and end user. Based on product type, the market is segmented as deep brain stimulator, spinal cord stimulator, vagus nerve stimulator, splanchnic nerve stimulator, autonomous nerve stimulator, and other. On the basis of end-user, the market is categorized as hospitals, clinics, and ambulatory surgical centers.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the obesity treating neuromodulation system market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The obesity treating neuromodulation system market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting obesity treating neuromodulation system market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely, North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the obesity treating neuromodulation system market in these regions.
Get more information on this report :
The report covers key developments in the obesity treating neuromodulation system market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from obesity treating neuromodulation system market are anticipated to have lucrative growth opportunities in the future with the rising demand for obesity treating neuromodulation system in the global market. Below mentioned is the list of few companies engaged in the obesity treating neuromodulation system market.
The report also includes the profiles of key players in obesity treating neuromodulation system market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
Leptos Medical, Inc.
St. Jude Medical, Inc.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Get more information on this report :
The List of Companies
1. BioControl Medical
2. Leptos Medical, Inc.
3. EnteroMedics, Inc.
4. Nevro Corp.
7. ReShape Lifesciences
8. Medtronic plc.
9. Cyberonics, Inc.
10. St. Jude Medical, Inc.